Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer.
Gupta N, Huang TT, Nair JR, An D, Zurcher G, Lampert EJ, McCoy A, Cimino-Mathews A, Swisher EM, Radke MR, Lockwood CM, Reichel JB, Chiang CY, Wilson KM, Cheng KC, Nousome D, Lee JM. Gupta N, et al. Among authors: cimino mathews a. Sci Transl Med. 2023 Jun 21;15(701):eadd7872. doi: 10.1126/scitranslmed.add7872. Epub 2023 Jun 21. Sci Transl Med. 2023. PMID: 37343085 Free PMC article. Clinical Trial.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L. Kim HS, et al. J Clin Oncol. 2016 Dec 20;34(36):4390-4397. doi: 10.1200/JCO.2016.67.7195. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998227 Free PMC article.
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC. Lee JM, et al. J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471727 Free PMC article. Clinical Trial.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. Zimmer AS, et al. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. J Immunother Cancer. 2019. PMID: 31345267 Free PMC article. Clinical Trial.
119 results